These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 32360890)

  • 21. Targeting CXCL12-CXCR4 Signaling Enhances Immune Checkpoint Blockade Therapy Against Triple Negative Breast Cancer.
    Lu G; Qiu Y; Su X
    Eur J Pharm Sci; 2021 Feb; 157():105606. PubMed ID: 33131745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
    Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
    Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
    Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
    J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liposomal ATM siRNA delivery for enhancing triple-negaitive breast cancer immune checkpoint blockade therapy.
    Yu D; Wang H; Liu H; Xu R
    J Biomater Appl; 2023 May; 37(10):1835-1846. PubMed ID: 37016537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model.
    Camilio KA; Wang MY; Mauseth B; Waagene S; Kvalheim G; Rekdal Ø; Sveinbjørnsson B; Mælandsmo GM
    Breast Cancer Res; 2019 Jan; 21(1):9. PubMed ID: 30670061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts.
    Wu Y; Yi Z; Li J; Wei Y; Feng R; Liu J; Huang J; Chen Y; Wang X; Sun J; Yin X; Li Y; Wan J; Zhang L; Huang J; Du H; Wang X; Li Q; Ren G; Li H
    Theranostics; 2022; 12(10):4564-4580. PubMed ID: 35832090
    [No Abstract]   [Full Text] [Related]  

  • 29. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.
    Gao M; Wang T; Ji L; Bai S; Tian L; Song H
    Front Immunol; 2020; 11():366. PubMed ID: 32194569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liposomal co-delivery of toll-like receptors 3 and 7 agonists induce a hot triple-negative breast cancer immune environment.
    Nguyen BL; Phung CD; Pham DV; Le ND; Jeong JH; Kim J; Kim JH; Chang JH; Jin SG; Choi HG; Ku SK; Kim JO
    J Control Release; 2023 Sep; 361():443-454. PubMed ID: 37558053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
    Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE
    ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer.
    Qiu X; Qu Y; Guo B; Zheng H; Meng F; Zhong Z
    J Control Release; 2022 Jan; 341():498-510. PubMed ID: 34883139
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Chen Q; Xiao H; Hu L; Huang Y; Cao Z; Shuai X; Su Z
    Adv Sci (Weinh); 2024 Sep; 11(36):e2401182. PubMed ID: 39051482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Walking Dead Tumor Cells for Targeted Drug Delivery Against Lung Metastasis of Triple-Negative Breast Cancer.
    Zhao Z; Fang L; Xiao P; Sun X; Zhou L; Liu X; Wang J; Wang G; Cao H; Zhang P; Jiang Y; Wang D; Li Y
    Adv Mater; 2022 Aug; 34(33):e2205462. PubMed ID: 35759925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer.
    Vito A; Rathmann S; Mercanti N; El-Sayes N; Mossman K; Valliant J
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34063642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hainanenin-1, an oncolytic peptide, triggers immunogenic cell death via STING activation in triple-negative breast cancer.
    Li X; Su N; Yu H; Li X; Sun SL
    Cell Commun Signal; 2024 Jul; 22(1):352. PubMed ID: 38970078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor Microenvironment Multiple Responsive Nanoparticles for Targeted Delivery of Doxorubicin and CpG Against Triple-Negative Breast Cancer.
    Gu F; Hu C; Cao W; Li C; Xia Q; Gao Y; Liu Y; Gao S
    Int J Nanomedicine; 2022; 17():4401-4417. PubMed ID: 36164553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Codelivery of Shikonin and siTGF-β for enhanced triple negative breast cancer chemo-immunotherapy.
    Li J; Zhao M; Liang W; Wu S; Wang Z; Wang D
    J Control Release; 2022 Feb; 342():308-320. PubMed ID: 35031387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Mechanism of a Biomimetic Nanosystem Carrying Doxorubicin and an IDO Inhibitor for Treatment of Advanced Triple-Negative Breast Cancer.
    Hu C; Liu Y; Cao W; Li N; Gao S; Wang Z; Gu F
    Int J Nanomedicine; 2024; 19():507-526. PubMed ID: 38260240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CXCL14 Attenuates Triple-Negative Breast Cancer Progression by Regulating Immune Profiles of the Tumor Microenvironment in a T Cell-Dependent Manner.
    Gibbs C; So JY; Ahad A; Michalowski AM; Son DS; Li Y
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.